Medivation, Inc. (NASDAQ:MDVN) went lower by -0.19% to close at $ 80.27. The company exchanged total volume of 16.75 million shares throughout course of last trade however it holds an average trading capacity of 3.03 million shares. Shares of company began trading at $80.40 climbed to high of $80.50 touched the low of $80.26.
The company is trading above its 50-day moving averages of 64.36 and up from 200-day moving averages of 53.13. The firm has price to book ratio of 24.94 and its price to sale ratio was 12.99.
According to ZACKS data, different Brokerage Firms rated the stock about their BUY, SELL or HOLD recommendations. Currently shares have been suggested as “BUY” from “0” brokerage firms and recommended as “Strong Buy” by “6” brokerage firms. 0” brokerage firms have issued “Sell” rating for the company and “Strong Sell” rating was issued by “0” brokerage firms. “8” brokerage firms have rated the company as a “Hold”. The Corporation has average brokerage recommendation (ABR) of 2.14 based on consensus of the brokerage firms issuing ratings.
The average true range of Medivation, Inc.’s (MDVN) is recorded at 1.89 and the relative strength index of the stock stands 90.96. The stock price is going above to its 52 week low with 203.94% and lagging behind from its 52 week high with -0.50%. Analyst recommendation for this stock stands at 2.10. A look on the firm performance, its monthly performance is 27.19% and a quarterly performance of 29.66%. The stock price is trading upbeat from its 200 days moving average with 63.60% and up from 50 days moving average with 28.46%.
Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) dropped -10.39% and closed the trade at $ 7.42. The company recorded a trading capacity of 955.7 thousand shares above its three months average daily volume of 390.72 thousand shares. During the last trade, shares reached to high price of $8.19 and touched the low price of $6.98. The stock’s 50-day moving average is noted at $5.41 and its 200-day moving average is stands at $5.00.
Additionally, the company has EPS of -4.18. The company has market capitalization of $23.14M.
The stock has received ratings from many brokerage firms according to ZACKS. Currently shares have been rated as “Buy” from “0” brokerage firms and “1” brokerage firms say as “Strong Buy”. “0” brokerage firms have suggested “Sell” for the company. “0” brokerage firms have recommended as a “Hold”. Strong Sell rating was given by “0” brokerage firms. The Company has average brokerage recommendation (ABR) of “1” based on consensus of the ZACKS brokerage firms.
Cyclacel Pharmaceuticals, Inc.’s (CYCC) has price-to-cash ratio of 1.58 and price to sale ratio of 16.72. A look on the firm performance, its monthly performance is 58.21% and a quarterly performance of 1852.63%. The stock price is moving up from its 20 days moving average with 31.84% and isolated positively from 50 days moving average with 39.53%.